VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment o... ( First Selective TLR8 Agonist to Advan...)

HOME >> MEDICINE >> TECHNOLOGY

VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment of Oncology

Date:12/4/2008

First Selective TLR8 Agonist to Advance to Clinical Trials

SAN DIEGO, Dec. 4 /PRNewswire/ -- VentiRx Pharmaceuticals, Inc., a biopharmaceutical company focused on the development of novel Toll-Like Receptor 8 (TLR8) agonists for the treatment of cancer, respiratory and autoimmune diseases, announced today that it has initiated a Phase I clinical trial of VTX-2337, a selective TLR8 agonist for the treatment of cancer. The multi-center clinical trial is being conducted at the Mayo Clinic Arizona and TGen Drug Development Services (TD2) both in Scottsdale, Arizona.

"We are delighted to advance the first molecule from our Toll-Like Receptor 8 platform, VTX-2337, into the clinic," said Michael Kamdar, Executive Vice President and Chief Business Officer at VentiRx. "This represents a significant milestone for VentiRx and our TLR efforts as we have rapidly advanced into a clinical development company with a novel molecule that may have broad application in the treatment of cancer."

VTX-2337 is a small molecule TLR8 agonist that is expected to be used in combination with standard of care for the treatment of patients with cancer. Preclinical evaluation of VTX-2337 suggests that it may play a key role in augmenting the innate arm of the immune system and provide a valuable addition to various treatment regimens in oncology. The first clinical trial will investigate the safety and pharmacology of multiple doses of VTX-2337 in patients with late stage cancer.

"VTX-2337 is the first selective TLR8 compound to reach the clinic and we are hopeful that modulation of the innate immune response will provide a benefit to patients in a number of oncology indications," said Dr. Robert Hershberg, Executive Vice President and Chief Medical Officer at VentiRx.

About VentiRx Pharmaceuticals

VentiRx Pharmaceuticals, Inc. is a biopharmaceutical company committed t
'/>"/>

SOURCE VentiRx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2
Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate

Post Your Comments:

(Date:11/20/2009)...., Nov. 20 /PRNewswire-FirstCall/ -- Landauer, ... the fiscal fourth quarter and full year of 2009 p...company will host a conference call for investors ... Time. Investors may access the live call by diali...da), or 480-629-9835 (international callers), or b...

(Date:11/20/2009)..., Nov. 20 Reportlinker.com announc...in its catalogue. ,, Blood Pressure Monitoring...alysis ,, http://www.reportlinker.com/p01643...nts---A-World-Market-Analysis.html#utm_source=prne...re ,, Measurement of blood pressure is not on...

(Date:11/20/2009)..., Nov. 20 ,, Reportlinker.com ...ilable in its catalogue. ,, India Medical Equi... http://www.reportlinker.com/p0164658/India-Medi...5.html#utm_source=prnewswire&utm_medium=pr&..., India Medical Equipment Market Analysis and For...

[0] Landauer, Inc. Sets Date and Time for Announcement of Fiscal Fourth Quarter and Full Year 2009 Results [0] Reportlinker Adds Blood Pressure Monitoring & Measurement Instruments - A World Market Analysis [0] Reportlinker Adds India Medical Equipment Market Analysis and Forecasts to 2015

...irst Approved Systemic Therapy to Treat the Diseas...,Bayer HealthCare Pharmaceuticals and Onyx Pharmac... The New England Journal of Medicine published,res...(R) (sorafenib),tablets decreased the absolute ris...able hepatocellular carcinoma (HCC), or liver canc...

...23 Sound Pharmaceuticals (SPI) has filed,an Inves...he clinical,testing of a proprietary formulation o...ed hearing loss or ototoxicity. The oral capsule,c...anced stage lung cancer,and head and neck cancer p...s marks the second development program for SPI to ...

Other Medicine Technology:The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 2 The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 3 The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 4 The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 5 The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer 6 Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer 2

The New England Journal of Medicine Publishes Nexavar(R) Study Demonstrating Significant Improvement in Overall Survival in Patients With Liver Cancer Sound Pharmaceuticals Files Second IND with the FDA for the Prevention of Chemotherapy Induced Hearing Loss in Advanced Stage Cancer

(Date:11/21/2009)... HAPPYneuron,s most popular and addi...hone and iPod Touch. , Mo...neuron,s most popular and addictive game, SplitWor... Split Words is designed to help banish that ,tip ...ds iPhone brain game challenges the brain by enc...

(Date:11/21/2009)... New Haven Dental Group merges their... Branford, CT. , (PRWEB) ...omprised of partners Dr. David Gibson, Dr. Dean Cl...r has just merged their growing practice with that...When Dr. Pickman decided he wanted to retire from ...

(Date:11/20/2009)...Pioneering Neurologist Closer to Understanding Bra...PRNewswire-USNewswire/ -- Dr. Jeremy Schmahmann, P...d neurologist at the Massachusetts General Hospita...is laboratory,s research on the new field of study...nk Foundation. ,, Dr. Schmahmann is an award-wi...

(Date:11/20/2009)..., WASHINGTON, Nov. 20 T...ators to modify health care reform legislation rel...ding a health insurance individual coverage mandat...eable mandate will minimize adverse selection stem...prescribed by the bill. ,, "The individual mand...

(Date:11/20/2009)...QUINCY, Mass., Nov. 20 Following a...t Company removed from sale Shedd,s Country Crock ...d Shedd,s Country Crock ® Side Dishes DELUXE ...ergen. ,, The following code dates and UPCs ar...de Dishes DELUXE Cheddar Broccoli Rice 21 oz, UPC ...

Breaking Medicine News(10 mins):Health News:HAPPYneuron releases iPhone Brain Game 2 Health News:HAPPYneuron releases iPhone Brain Game 3 Health News:New Haven Dental Group Expands Their Vision 2 Health News:MINDlink Foundation Launches to Connect the Cerebellum to Cures 2 Health News:Actuaries to Senate: Strengthen Individual Mandate 2 Health News:Stop & Shop Alerts Customers to Voluntary Recall by Unilever 2

[0] HAPPYneuron releases iPhone Brain Game [0] New Haven Dental Group Expands Their Vision [0] MINDlink Foundation Launches to Connect the Cerebellum to Cures [0] Actuaries to Senate: Strengthen Individual Mandate [0] Stop & Shop Alerts Customers to Voluntary Recall by Unilever

... Winegrowers are affected by the type 3 virus whic...y of grapevines//. But most of the winegrowers...are tested vines and are free from the virus. New ...management and detection. Mr Manson said that the ...

...arenicline or Chantix promises to be more effectiv...the habit In addition it has also shown to promote...lts of three studies published in the Journal of t...t dopamine release to curb cravings and at the sam...

...ue to the several previous studies, Geoffrey R. Ho... his colleagues have revealed that exposure// to r...ens and kids. After the chornobyl radiation-ac...adioactive iodine. In 1986, an accident at the...

... unions have accused the Government; of trying to ...uraged and called on large private// sector compan...services. Explaining that the notice on the ...ice-provider to a commissioning-led organisation.'...

...ficials have reported that inhabitants of Phet whe...ered about bird flu// since they had a feast on th...wer northern province of Phichit are trying to cre...it to the area that people were disregarding the t...

...ajor Wyeth Tuesday launched its blockbuster vaccin...ococcal disease among infants and toddlers//. ...ed by streptococcus pneumoniae, also known as the ...l pneumonia, septicaemia and bacteraemia (bacteria...

Other Medicine News:Health News:New Drug to Help Smokers Kick the Habit 2 Health News:Chornobyl Incident Proved Increased Risk of Thyroid Cancer from Radioactive Iodine 2 Health News:Government Accused Of Yielding NHS To Outside Interests 2

Leaf Roll Disease a Cause of Concern to Wine Growers New Drug to Help Smokers Kick the Habit Chornobyl Incident Proved Increased Risk of Thyroid Cancer from Radioactive Iodine Government Accused Of Yielding NHS To Outside Interests People In Thailand Not Bothered About Bird Flu Wyeth Launches Vaccine for Pneumococcal Disease in India

Steinman Pins, Threaded

Skeletal Traction Pins, Half Pin with Cove Point

Skeletal Traction Pins, Full Pin with Cove Point

Instera Pins

Medicine Products:

Steinman Pins, Threaded Skeletal Traction Pins, Half Pin with Cove Point Skeletal Traction Pins, Full Pin with Cove Point Instera Pins

VentiRx Pharmaceuticals Commences Phase I Clinical Trial of VTX-2337, a Novel TLR8 Agonist for the Treatment o...( First Selective TLR8 Agonist to Advan...),Health